THE TAPE

Eton Pharmaceutcials, Inc. Common Stock

$63.88▼ −0.08%
Last close
Relative strength
98RS
of 99, against every stock• 0 on the month
Powering up
Developing
+77.0%
six months against Pharmaceutical Preparations
52-week range
−9.6%
from the high
$14.27$70.64
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof SHOWN
Quarter to Sep 30, revenue +158% on a year ago
Why it is on no screen

ETON passes every check below but is not on a screen — the screens also require the base to be the most recent structure, which this one is not.

A base has formed11.0 weeks, from 47.03 to 66.37.
Long enough to count11.0 weeks against 3 needed.
Shallow enough29.1% deep against 35% allowed.
Close to its pivot-3.8% from the pivot; listed down to -20%.
Relative strengthRS 98 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$60.21
-5.7% · tested 3× · last 36 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Eton Pharmaceutcials, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 98, and it sits in Pharmaceutical Preparations.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+21.6%
Three months against its industry
+16.4%
Six months against its industry
+77.0%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 12.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$141.1M
+157.9% year on year
Operating margin
28.8%
gross 69.2%
Net margin
35.3%
Free cash flow
$38.2M
2.1% of market cap
Price to sales
12.9×
Price to earnings
36.6×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$57.9M
+54.1% QoQ · +157.9% YoY
Gross margin
76.5%
+8.9 pts QoQ
Net income
$35.2M
Positive
Free cash flow
$35.2M
Cash generating

What the numbers say

  • Good: Revenue +157.9% year over year, +54.1% on the quarter
  • Good: Gross margin 76.5%, +8.9 points on the quarter
  • Good: Profitable: net income $35M, operating margin 39.7%
  • Good: Cash generating: operating cash flow $35M, free cash flow $35M
  • Weak: Share count +23.7% in a year: dilution
  • Good: Net cash $33M · cash $56M
Revenue by quarter
Free cash flow
Net income
shares +23.7% in a year · net cash $32.6M

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: REAL · Economic proof: SHOWN
Key question: Does the next quarter repeat this one?
The next test is funding the growth from operations: share count +23.7% in a year: dilution.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-10.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week highTape · 2026-11-11
2.0x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-10
above 20d & 50d on 2.0x volume at 64.35
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-10
+14.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-10
+14.0% on earnings 2026-11-09
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
GappedTape · 2026-11-07
+19.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-07
+19.8% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Reported resultsFiling · 2026-11-06
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
24
$25,408,606 total

Sold: Krempa David, MAIER PAUL V, BRYNJELSEN SEAN, Opaleye Management Inc., Adams Jennifer McKie.

Not counted above: 12 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-06 Krempa David · Chief Business Officersell4,166$229,406
2026-10-02 Krempa David · Chief Business Officeroption exercise10,522
2026-08-28 MAIER PAUL V · Directoroption exercise50,000$189,000
2026-08-28 MAIER PAUL V · Directorsell36,387$2,133,734
2026-08-28 MAIER PAUL V · Directorsell13,485$811,932
2026-08-28 MAIER PAUL V · Directorsell128$7,907
2026-08-24 Krempa David · Chief Business Officeroption exercise25,000$182,750
2026-08-24 Krempa David · Chief Business Officersell25,000$1,626,750

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy0
Buy4
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Eton Pharmaceutcials, Inc. Common Stock (ETON) — The Tape